

OCT 06 2003  
TM TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 10034-004-999	APPLICATION NO 10/067,146
APPLICANT Siegal et al.		RECEIVED OCT 10 2003 TECH CENTER 1600/2900	
FILING DATE February 4, 2002		GROUP 1636	

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
g	A01	5,676,942	10/14/97	Testa et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

g	C01	Abb et al., 1983, "Phenotype of human alpha-interferon producing leucocytes identified by monoclonal antibodies," Clin Exp Immunol. 52(1):179-84
g	C02	Autran et al., 1997, "Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease," Science 277(5322):112-6
g	C03	Bandyopadhyay et al., 1986, "Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts," J Exp Med. 164(1):180-95
g	C04	Brinkmann et al., 1993, "Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells," J Exp Med. 178(5):1655-63
g	C05	Bubenik, 1996, "Cytokine Gene-Modified Vaccines in the Therapy of Cancer," Pharmacol. Ther. 69(1):1-14
g	C06	Cederblad et al., 1991, "Interferons and the colony-stimulating factors IL-3 and GM-CSF enhance the IFN-alpha response in human blood leucocytes induced by herpes simplex virus," Scand J Immunol. 1991 Nov;34(5):549-55
g	C07	Chehimi et al., 1989, "Dendritic cells and IFN-alpha-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood," Immunology 68(4):488-90
g	C08	Clerici et al., 1994, "The Th1-Th2 hypothesis of HIV infection: new insights," Immunol Today 15(12):575-81 Review
g	C09	Dong et al., 1999, Cancer Res. 59:872-879
g	C10	Eck et al., 1996, "Gene-Based Therapy," Pharmacological Basis of Therapeutics, Chapter 5: 77-101
g	C11	Empson et al., 1999, "Atopy, anergic status, and cytokine expression in HIV-infected subjects," J Allergy Clin Immunol. 103(5 Pt 1):833-42
g	C12	Feldman et al., 1995, J. Leuk. Biol. 57:214-220
g	C13	Feldman et al., 1994, Virology 204:1-7
g	C14	Feldman et al., 1990, J. Interferon Res. 10:435-446
g	C15	Ferbas et al., 1995, Clin. Diagn. Lab. Immunol. 2:138-142
g	C16	Ferbas et al., 1994, J. Immunol. 152:4649-4662
g	C17	Fitzgerald-Bocarsly, 1993, Pharmacol. Ther. 60:39-62
g	C18	Fitzgerald-Bocarsly, 1988, J. Leuk. Biol. 43:323-334
g	C19	Ghanekar et al., 1996, J. Immunol. 157:4028-4036
g	C20	Grouard et al., 1997, J. Exp. Med. 185:1101-1111 (or Grouard)
g	C21	Harrison et al., 1997, J. Immunol. 158:459-463
g	C22	Howell et al., 1994, Clin. Immunol. Immunopathol. 71(2):223-230

Q	C23	Isaacs et al., 1957, Proc. R. Soc. London 147:25B
Q	C24	Kirchner et al., 1979, Immunobiology 156:65-75
J.HALDEMAN 82	C25	Komanduri et al., 1998, Nat. Med. 4:953-956
Q	C26	Kostense et al., 1998, AIDS 12:F235-240
Q	C27	Ledergerber et al., 1999, J. Amer. Med. Assn. 282:2220-2226
Q	C28	Lederman et al., 1998, J. Inf. Dis. 178:70-79
Q	C29	Ledley, 1991, Human Gene Therapy 2:77-83
Q	C30	Leigh et al., 1998, J. Acquir. Immune Def. Syndr. Hum. Retrovirol. 19:373-380
Q	C31	Lopez et al., 1983, J. Inf. Dis. 148:962-966
Q	C32	Marrack et al., 1999, J. Exp. Med. 189:52
Q	C33	Milone et al., 1998, J. Immunol. 161:2391-2399
Q	C34	Mcroft et al., 1998, Lancet 352:1725-1730
Q	C35	O'Doherty et al., 1994, Immunology 82:487
Q	C36	O'Doherty et al., 1993, J. Exp. Med. 178:1067
Q	C37	Olweus et al., 1997, PNAS USA 94:125551
Q	C38	Pakker et al., 1998, Nat. Med. 4:208-214
Q	C39	Palella et al., 1998, N. Engl. J. Med. 338:853-860
Q	C40	Parronchi et al., 1996, Eur. J. Immunol. 26:697-703
Q	C41	Payvandi et al., 1998, J. Immunol. 160:5861-5868
Q	C42	Perussia et al., 1985, Nat. Immunol. Cell Growth Regul. 4:120-137
Q	C43	Peter et al., 1980, Eur. J. Immunol. 10:547-555
Q	C44	Pontesilli et al., 1999, Immunol. Lett. 66:213-217
Q	C45	Powderly et al., 1998, J. Amer. Med. Assoc. 280:72-77
Q	C46	Qin et al., 1998, PNAS 95:14411-14416
Q	C47	Rappoccio et al., 1989, J. Clin. Microbiol. 27:41-48
Q	C48	Rissoan et al., 1999, Science 283:1183-1186
Q	C49	Rogge et al., 1998, J. Immunol. 161:6567-6574
Q	C50	Sandberg et al., 1991, Scan. J. Immunol. 34:565-576
Q	C51	Sandberg et al., 1990, J. Immunol. 145:1015-1020
Q	C52	Sanhadji et al., 1997, AIDS 11:977-986
Q	C53	Schneider et al., 1999, Lancet 353:201-203
Q	C54	Shodell, M., FP Siegal: abstract submitted, FASEB AAI/CIS Congress, Seattle, WA, May, 2000
Q	C55	Siegal et al., 1999, Science 284:1835-1837
Q	C56	Siegal et al., 1994, Leukemia 8:1474-1479
Q	C57	Siegal et al., 1986, J. Clin. Invest. 78:115-123
Q	C58	Starr et al., 1993, Acv. Exp. Med. Biol. 329:173-178
Q	C59	Sun et al., 1998, J. Exp. Med. 188:2335
Q	C60	Svensson et al., 1996, J. Interferon Cytok. Res. 16:7-16
Q	C61	Svensson et al., 1996, Scan. J. Immunol. 44:164-172
Q	C62	Viillard et al., 1997, PNAS 94:11595-11600

EXAMINER

*James R. Kuykendall*

DATE CONSIDERED

11/12/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.